Angiogenesis and VEGF in Cancer
Angiogenesis and VEGF in Cancer is a research topic within Molecular Biology. Science Explorer counts 38k research works in it since 1950. 9.9% of them reached the world's top 10% most cited for their field and year.
This cluster of papers focuses on the molecular mechanisms of angiogenesis, including the role of VEGF, endothelial progenitor cells, pericytes, and anti-angiogenic therapy in regulating tumor vasculature and vascular function. It explores the signaling pathways, therapeutic targets, and clinical applications related to angiogenesis.
- VEGF
- endothelial progenitor cells
- tumor angiogenesis
- anti-angiogenic therapy
- vascular endothelial growth factor
- pericytes
- vascular normalization
- endothelial cell behavior
- tumor vasculature
- angiogenic signaling
- Research works
- 38k fractional, since 1950
- In the world top 10%
- 3.8k per year above
- Top-10% rate
- 9.9% share of its works in the world top 10%
- Growth, 2018-21 → 2022-25
- -14% the tick is no change
- Largest producer
China
39% of the 10 largest, 2022-now
Which countries lead Angiogenesis and VEGF in Cancer research?
By volume, China and the United States publish the most (1.3k and 922 works in 2022-now).
By volume, 2022-now
- 1
China 1.3k works
- 2
United States 922 works
- 3
Japan 228 works
- 4
Germany 184 works
- 5
Italy 156 works
- 6
India 151 works
- 7
United Kingdom 139 works
- 8
South Korea 127 works
- 9
France 96 works
- 10
Russia 87 works
How concentrated that is
The same countries as shares of everything the list above accounts for. A node where two countries do two thirds of the work and one spread evenly across twelve read alike as a ranking and not at all alike here.
Shares of the rows listed above, not of the whole node.
Which institutions lead Angiogenesis and VEGF in Cancer research?
By volume in 2022-now, Harvard University publishes the most Angiogenesis and VEGF in Cancer research, followed by Sun Yat-sen University and Shanghai Jiao Tong University.
By volume, 2022-now
- 1
Harvard University
United States 47 works
- 2
Sun Yat-sen University
China 42 works
- 3
Shanghai Jiao Tong University
China 41 works
- 4
Zhejiang University
China 32 works
- 5
Fudan University
China 27 works
- 6
Sichuan University
China 27 works
- 7
Nanjing Medical University
China 27 works
- 8
Chinese Academy of Medical Sciences & Peking Union Medical College
China 27 works
- 9
Capital Medical University
China 26 works
- 10
University of Bari Aldo Moro
Italy 22 works
Who are the leading researchers in Angiogenesis and VEGF in Cancer?
The most-cited researchers publishing on Angiogenesis and VEGF in Cancer include Robert John Tibshirani, Bert Vogelstein and Jost Bruno Jonas.
- 1
Robert John Tibshirani
United States 396k citations
- 2
Bert Vogelstein
United States 373k citations
- 3
Jost Bruno Jonas
Germany 350k citations
- 4
Emelia J. Benjamin
United States 341k citations
- 5
Jun Wang
China 340k citations
- 6
Stephan Windecker
Switzerland 338k citations
- 7
Giuseppe Remuzzi
Italy 328k citations
- 8
Graeme J. Hankey
Australia 316k citations
- 9
Gordon Henry Guyatt
Canada 315k citations
- 10
Gregory Y.H. Lip
United Kingdom 311k citations
Ranked by citations received across their whole record, among researchers with at least three works on this topic.
Where is Angiogenesis and VEGF in Cancer research done?
The largest centres of Angiogenesis and VEGF in Cancer research in 2022-now are Beijing (China), Shanghai (China), Guangzhou (China) and Seoul (South Korea). Among places with at least 20 works in it, it is an unusually large share of all research in Bari.
Largest cities, 2022-now
Where it is the local speciality
- BariIT · 24.7 works9.8×
Location quotient: how much more of its research is in Angiogenesis and VEGF in Cancer than the world average.
Where is the best place to study Angiogenesis and VEGF in Cancer?
Among universities, judged by research, Harvard University, KU Leuven and Chinese Academy of Medical Sciences & Peking Union Medical College score highest, combining citation excellence, specialisation, size, growth and international reach. Research strength is one signal when choosing where to study; it does not measure teaching.
One dot per university in the first ten of the table below, at the default weights. The upper left is the interesting corner: small places doing unusually strong work.
Universities only. The score blends citation excellence (40%), size (30%), specialisation (10%), growth (10%), international reach (10%), 2022-now; growth compares 2018-21 with 2022-25 and counts up to +20%, since a jump from a small base is mostly noise.
Every institution in Angiogenesis and VEGF in Cancer, country by countryIs Angiogenesis and VEGF in Cancer research growing?
Output in 2022-2025 was 14% lower than in 2018-2021, peaking in 2012.
The same series as a ribbon: one cell per year, darker for more. The line above answers how much; this answers when.
Its share of all research
Growing output can still be a shrinking share: all of science grows. This is Angiogenesis and VEGF in Cancer as a percentage of every work published that year, 0.016% in 2024.
Fractional works of Angiogenesis and VEGF in Cancer over all fractional works that year. How the balance of science has shifted.
How much of it reaches the world top 10%
Year by year.
Of each year's works in it, the share that reached the world's 10% most cited for their field and year. A field is the world for its own topics, so there is no other line to hold it against.
Which topics inside it are moving
Growth and decline on one axis around a shared zero. Two lists side by side hide the thing that matters: whether the growth dwarfs the decline, or the other way round.
Discussion
Ask a question or share a note about Angiogenesis and VEGF in Cancer. Keep it to the research: no personal attacks, advertising or links. Any reader can report a post, which collapses it for everyone until it is opened.